<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770509</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA -11- 9204-SG-CTIL</org_study_id>
    <nct_id>NCT01770509</nct_id>
  </id_info>
  <brief_title>The Effect of the Cosmetic Cream NMBM on Leg Ulcers - a Pilot Study</brief_title>
  <official_title>A Randomized, Parallel Group, Controlled Study to Assess the Efficacy and Safety of NMBM in the Treatment of Subjects With a Post-cellulitis and Venous Leg Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Lederman Consulting Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Lederman Consulting Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcers of the lower extremities, caused by chronic venous insufficiency and cellulitis are
      common in patients older than 65 years and cause a significant morbidity.

      Natural Matrix Bio polymer Membrane (NMBM) is a novel topical cosmetic cream containing a mix
      of natural waxes, sugars and lipids. The aim of this study is to test whether of Natural
      Matrix Bio polymer Membrane (NMBM) is effective as an adjunctive therapy to the treatment of
      venous stasis and post-erysipelas leg ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ulcers of the lower extremities, particularly in patients older than 65 years, are common
      among the population. Studies estimate the prevalence of current chronic leg ulcers at
      approximately 1%. The most common cause (approximately 80%) is thought to be chronic venous
      insufficiency disease. Recurrent cellulitis is an additional common cause. The ulcers cause a
      significant morbidity and negative impact on the patients' quality of life. The care of
      chronic vascular ulcers places a significant burden on the patient and the health care
      system. Additionally, these nonhealing ulcers place the patient at much higher risk for lower
      extremity amputation.

      Natural Matrix Bio polymer Membrane (NMBM) is a novel topical cosmetic cream containing a mix
      of natural waxes, sugars and lipids. The aim of this study is to test whether of Natural
      Matrix Bio polymer Membrane (NMBM) is effective as an adjunctive therapy to the treatment of
      venous stasis and post-erysipelas leg ulcers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Logarithm of Percentage of Baseline Ulcer Size</measure>
    <time_frame>From start of treatment to 4 weeks</time_frame>
    <description>Logarithm of percentage of baseline ulcer size. Log (ulcer area at 4 weeks/ulcer area at baseline *100) Ulcer area measured as longest ulcer length x longest ulcer width</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alleviation of Pain</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pain in week 4, assessed by the patient on a visual analogue pain score from 0 to 10. 0 represents no pain, 10 represents worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events at 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of patients with adverse effects at 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of adverse effects at 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Closure</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ulcer</condition>
  <condition>Venous Ulcer</condition>
  <condition>Skin Ulcer</condition>
  <condition>Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care: Dressings +Compression garments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Application of NMBM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily application of NMBM</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NMBM</intervention_name>
    <description>Daily application of NMBM in addition to compression therapy</description>
    <arm_group_label>Application of NMBM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Compression garments</intervention_name>
    <description>Compression garments</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>Application of NMBM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated written Institutional Review Board (IRB) or Independent Ethics
             Committee (IEC) approved informed consent obtained from the subject in accordance with
             the local regulations;

          2. Male or female subjects, ≥18 to ≤90 years of age

          3. Patient with venous or predominantly venous leg ulcer (ankle-brachial index &gt; 0.8)

          4. Chronic venous insufficiency or post-erysipelas ulcer

          5. Ulcer size between 5 and 170 sq cm, inclusive

          6. Ulcer present for at least one month

          7. ankle-brachial index &gt;0.7

        Exclusion Criteria:

          1. Suffers from diabetes mellitus with HbA1c ≥ 8%

          2. Albumin less than

        2. 2. Patients with the following abnormal laboratory test levels hemoglobin &lt;10.5 g/dL
        platelet count &lt;100 x 109/L serum albumin level &lt; 2.5 g/dL 3. Suffers from clinically
        significant arterial disease 34. Has a known allergy to any of the compounds that are part
        of this protocol 45. Has evidence of the ulcer and / or infection extending to the
        underlying muscle, tendon or bone 56. Has used any investigational drug(s) within 30 days
        preceding randomization 67. Is unable to manage self-treatment 78. Is pregnant, nursing
        mother or a woman of child bearing potential who is not using an adequate form of
        contraception (or abstinence) 8. 9. Suffers from a condition which in the opinion of the
        Investigator would compromise the safety of the subject and / or the quality of the data 9.
        10. Unwilling or unable to comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoshana Greenberger, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Dermatology, Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Department of Dermatology, Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2013</study_first_posted>
  <results_first_submitted>May 17, 2015</results_first_submitted>
  <results_first_submitted_qc>November 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2017</results_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic venous leg ulcers</keyword>
  <keyword>Venous ulcer</keyword>
  <keyword>Stasis ulcer</keyword>
  <keyword>Varicose ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Skin Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care</title>
          <description>Standard of care: Dressings +Compression garments
Compression garments: Compression garments</description>
        </group>
        <group group_id="P2">
          <title>Application of NMBM</title>
          <description>Daily application of NMBM
NMBM: Daily application of NMBM in addition to compression therapy
Compression garments: Compression garments</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Injury</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care</title>
          <description>Standard of care: Dressings +Compression garments
Compression garments: Compression garments</description>
        </group>
        <group group_id="B2">
          <title>Application of NMBM</title>
          <description>Daily application of NMBM
NMBM: Daily application of NMBM in addition to compression therapy
Compression garments: Compression garments</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.54" spread="7.7"/>
                    <measurement group_id="B2" value="68.17" spread="13.9"/>
                    <measurement group_id="B3" value="70.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Logarithm of Percentage of Baseline Ulcer Size</title>
        <description>Logarithm of percentage of baseline ulcer size. Log (ulcer area at 4 weeks/ulcer area at baseline *100) Ulcer area measured as longest ulcer length x longest ulcer width</description>
        <time_frame>From start of treatment to 4 weeks</time_frame>
        <population>Analysis is based on measures from each ulcer, when some participants had more than one ulcer</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Dressings +Compression garments
Compression garments: Compression garments</description>
          </group>
          <group group_id="O2">
            <title>Application of NMBM</title>
            <description>Daily application of NMBM
NMBM: Daily application of NMBM in addition to compression therapy
Compression garments: Compression garments</description>
          </group>
        </group_list>
        <measure>
          <title>Logarithm of Percentage of Baseline Ulcer Size</title>
          <description>Logarithm of percentage of baseline ulcer size. Log (ulcer area at 4 weeks/ulcer area at baseline *100) Ulcer area measured as longest ulcer length x longest ulcer width</description>
          <population>Analysis is based on measures from each ulcer, when some participants had more than one ulcer</population>
          <units>Mean of log (percentage of baseline area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Ulcers</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Ulcers</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6043" spread="2.16636"/>
                    <measurement group_id="O2" value="3.5030" spread="2.11130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.652</p_value>
            <method>ANOVA</method>
            <method_desc>General Linear Model ANOVA with repeated measures</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alleviation of Pain</title>
        <description>Pain in week 4, assessed by the patient on a visual analogue pain score from 0 to 10. 0 represents no pain, 10 represents worst pain</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Dressings +Compression garments
Compression garments: Compression garments</description>
          </group>
          <group group_id="O2">
            <title>Application of NMBM</title>
            <description>Daily application of NMBM
NMBM: Daily application of NMBM in addition to compression therapy
Compression garments: Compression garments</description>
          </group>
        </group_list>
        <measure>
          <title>Alleviation of Pain</title>
          <description>Pain in week 4, assessed by the patient on a visual analogue pain score from 0 to 10. 0 represents no pain, 10 represents worst pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="1.29"/>
                    <measurement group_id="O2" value="1.68" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.645</p_value>
            <method>ANOVA</method>
            <method_desc>General Linear Model ANOVA with repeated measures</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events at 4 Weeks</title>
        <description>Number of patients with adverse effects at 4 weeks</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Dressings +Compression garments
Compression garments: Compression garments</description>
          </group>
          <group group_id="O2">
            <title>Application of NMBM</title>
            <description>Daily application of NMBM
NMBM: Daily application of NMBM in addition to compression therapy
Compression garments: Compression garments</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events at 4 Weeks</title>
          <description>Number of patients with adverse effects at 4 weeks</description>
          <units>Number of patients with adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of adverse effects at 4 weeks</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Dressings +Compression garments
Compression garments: Compression garments</description>
          </group>
          <group group_id="O2">
            <title>Application of NMBM</title>
            <description>Daily application of NMBM
NMBM: Daily application of NMBM in addition to compression therapy
Compression garments: Compression garments</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of adverse effects at 4 weeks</description>
          <units>number of adverse effects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Closure</title>
        <time_frame>4 weeks</time_frame>
        <population>Data was not collected as time to ulcer closure has been beyond the study period in the majority of patients</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Dressings +Compression garments
Compression garments: Compression garments</description>
          </group>
          <group group_id="O2">
            <title>Application of NMBM</title>
            <description>Daily application of NMBM
NMBM: Daily application of NMBM in addition to compression therapy
Compression garments: Compression garments</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Closure</title>
          <population>Data was not collected as time to ulcer closure has been beyond the study period in the majority of patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care</title>
          <description>Standard of care: Dressings +Compression garments
Compression garments: Compression garments</description>
        </group>
        <group group_id="E2">
          <title>Application of NMBM</title>
          <description>Daily application of NMBM
NMBM: Daily application of NMBM in addition to compression therapy
Compression garments: Compression garments</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>local irritation</sub_title>
                <description>Local erythema or burning</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>wound infection</sub_title>
                <description>Secondary infection of wound treated by antibiotics</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shoshana Greenberger</name_or_title>
      <organization>The Department of Dermatology, Sheba Medical Center</organization>
      <phone>972-3-5302443</phone>
      <email>shoshana.greenberger@sheba.health.gov.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

